Literature DB >> 33820745

Assessment of quality of life of the patients with diabetic retinopathy using National Eye Institute Visual Functioning Questionnaire (VFQ-25).

S Pawar1, A Parkar2, S Menon2, N Desai2, D Namrata2, K Dole3.   

Abstract

BACKGROUND: Diabetes affects most of the organs causing macrovascular and microvascular complications. Diabetic retinopathy (DR) results from the prolonged uncontrolled hyperglycemia which causes impairment of vision. Quality of life (QoL) of patients with DR is affected due to vision loss. National Eye Institute Visual Functioning Questionnaire (NEI-VFQ-25) is the questionnaire used to study the effect of DR on QoL.
OBJECTIVES: To assess the QoL of the patients with DR.
MATERIALS AND METHODS: The study enrolled 149 (male-104 and female 45) patients with DR. The previous translated and validated version of NEI-VFQ-25 questionnaire was used in the study.
RESULTS: Cronbach alpha for internal consistency was between 0.6 and 0.8. The male patient showed significantly higher (p<0.05) QoL scores (60.73±1.63) as compared to the female patients (53.15±2.84). Hypertensive patients showed poor QoL as compared to non-hypertensive patients. The patients with a history of diabetes for 16-30 yrs. showed better QoL as compared to other patients.
CONCLUSION: DR affects the QoL of life of patients. Routine assessment of QoL using NEI-VFQ-25 questionnaire would be useful for physicians and health care team.
Copyright © 2021 FECA. Publicado por Elsevier España, S.L.U. All rights reserved.

Entities:  

Keywords:  Calidad de vida; Diabetes; Quality of life; Retinopathy; Retinopatía

Year:  2021        PMID: 33820745     DOI: 10.1016/j.jhqr.2021.02.004

Source DB:  PubMed          Journal:  J Healthc Qual Res        ISSN: 2603-6479


  1 in total

1.  Chinese Version of the Vision-Related Quality of Life (NEI-VFQ-25) among Patients with Various Ocular Disorders: A Pilot Study.

Authors:  Jiahn-Shing Lee; Ken-Kuo Lin; Chiun-Ho Hou; Pei-Ru Li; Lai-Chu See
Journal:  Medicina (Kaunas)       Date:  2022-04-27       Impact factor: 2.948

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.